Date: 2015-03-23
Type of information: Nomination
Compound:
Company: Blueprint Medicines (USA - MA)
Therapeutic area: Cancer - Oncology - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 23, 2015, Blueprint Medicines announced the appointment of Charles A. Rowland Jr., CPA, to its Board of Directors. Mr. Rowland most recently served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, a global biopharmaceutical company with $500 million in revenues, until the company was acquired by Shire plc in January 2014. In this role, he oversaw all aspects of finance, including financial analysis and reporting, tax, treasury and investor relations, as well as strategic business planning and information technology. Before joining ViroPharma in 2008, Mr. Rowland was Executive Vice President and CFO, as well as interim Co-Chief Executive Officer, for Endo Pharmaceuticals, a specialty pharmaceutical company with $1.3 billion in revenues. He previously held finance positions of increasing responsibility at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia Corp., Novartis AG and Bristol-Myers Squibb Co. Mr. Rowland also serves as a director and chair of the audit committees of Aurinia Pharmaceuticals, BIND Therapeutics, Vitae Pharmaceuticals and Nabriva Therapeutics, AG. He holds an M.B.A. from Rutgers’s University and a B.S. from Saint Joseph’s University.
Financial terms:
Latest news:
